Movement Alert｜Elevance Health Rises 5.25% in Pre-Market Trading, Multiple Investment Banks Raise Price Targets Ahead of Q2 Earnings

Market Focus

Jul 14

On July 14, Elevance Health rose 5.25% in pre-market trading, trading at $442.15/share, with turnover of $334,800. The rally came as multiple Wall Street firms issued bullish price target revisions just ahead of the company's Q2 earnings release scheduled for July 15.

On the news front, Wells Fargo significantly raised its price target from $391 to $492 while maintaining an Overweight rating; Truist lifted its target to $475, keeping a Buy rating; and Bernstein raised its target to $482, maintaining an Outperform rating. The FactSet consensus target price has climbed to approximately $439. Market consensus expects Q2 revenue of $48.714 billion, representing 0.99% year-over-year growth, with adjusted EPS of $6.20.

The broader healthcare insurance sector is approaching a critical test as Elevance, UnitedHealth, and CVS Health report Q2 results sequentially. Goldman Sachs noted that underwriting conditions for managed care companies are improving. Elevance delivered a strong Q1 beat with adjusted EPS of $12.58 versus the $10.79 estimate, and management reaffirmed full-year adjusted EPS guidance of at least $26.75.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1105657461"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1105657461\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1105657461?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-14 21:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105657461","market":"us","top_or_hot":-1,"title":"Movement Alert｜Elevance Health Rises 5.25% in Pre-Market Trading, Multiple Investment Banks Raise Price Targets Ahead of Q2 Earnings","media":"Market Focus","content":"<p><p>On July 14, Elevance Health rose 5.25% in pre-market trading, trading at $442.15/share, with turnover of $334,800. The rally came as multiple Wall Street firms issued bullish price target revisions just ahead of the company's Q2 earnings release scheduled for July 15.</p><p>On the news front, Wells Fargo significantly raised its price target from $391 to $492 while maintaining an Overweight rating; Truist lifted its target to $475, keeping a Buy rating; and Bernstein raised its target to $482, maintaining an Outperform rating. The FactSet consensus target price has climbed to approximately $439. Market consensus expects Q2 revenue of $48.714 billion, representing 0.99% year-over-year growth, with adjusted EPS of $6.20.</p><p>The broader healthcare insurance sector is approaching a critical test as Elevance, UnitedHealth, and CVS Health report Q2 results sequentially. Goldman Sachs noted that underwriting conditions for managed care companies are improving. Elevance delivered a strong Q1 beat with adjusted EPS of $12.58 versus the $10.79 estimate, and management reaffirmed full-year adjusted EPS guidance of at least $26.75.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Elevance Health Rises 5.25% in Pre-Market Trading, Multiple Investment Banks Raise Price Targets Ahead of Q2 Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Elevance Health Rises 5.25% in Pre-Market Trading, Multiple Investment Banks Raise Price Targets Ahead of Q2 Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-14 21:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 14, Elevance Health rose 5.25% in pre-market trading, trading at $442.15/share, with turnover of $334,800. The rally came as multiple Wall Street firms issued bullish price target revisions just ahead of the company's Q2 earnings release scheduled for July 15.</p><p>On the news front, Wells Fargo significantly raised its price target from $391 to $492 while maintaining an Overweight rating; Truist lifted its target to $475, keeping a Buy rating; and Bernstein raised its target to $482, maintaining an Outperform rating. The FactSet consensus target price has climbed to approximately $439. Market consensus expects Q2 revenue of $48.714 billion, representing 0.99% year-over-year growth, with adjusted EPS of $6.20.</p><p>The broader healthcare insurance sector is approaching a critical test as Elevance, UnitedHealth, and CVS Health report Q2 results sequentially. Goldman Sachs noted that underwriting conditions for managed care companies are improving. Elevance delivered a strong Q1 beat with adjusted EPS of $12.58 versus the $10.79 estimate, and management reaffirmed full-year adjusted EPS guidance of at least $26.75.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ELV","symbol_name":"Elevance Health","start_time":0,"source_url":"","article_id":"1105657461","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105657461","pubTimestamp":1784035572,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 14, Elevance Health rose 5.25% in pre-market trading, trading at $442.15/share, with turnover of $334,800. The rally came as multiple Wall Street firms issued bullish price target revisions...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ELV":"Elevance Health"},"translate_title":"走势警报|Elevance Health 在盘前交易中上涨 5.25%，多家投资银行在第二季度收益公布前上调目标价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ELV":1},"content_text":"On July 14, Elevance Health rose 5.25% in pre-market trading, trading at $442.15/share, with turnover of $334,800. The rally came as multiple Wall Street firms issued bullish price target revisions just ahead of the company's Q2 earnings release scheduled for July 15.On the news front, Wells Fargo significantly raised its price target from $391 to $492 while maintaining an Overweight rating; Truist lifted its target to $475, keeping a Buy rating; and Bernstein raised its target to $482, maintaining an Outperform rating. The FactSet consensus target price has climbed to approximately $439. Market consensus expects Q2 revenue of $48.714 billion, representing 0.99% year-over-year growth, with adjusted EPS of $6.20.The broader healthcare insurance sector is approaching a critical test as Elevance, UnitedHealth, and CVS Health report Q2 results sequentially. Goldman Sachs noted that underwriting conditions for managed care companies are improving. Elevance delivered a strong Q1 beat with adjusted EPS of $12.58 versus the $10.79 estimate, and management reaffirmed full-year adjusted EPS guidance of at least $26.75.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}